宁夏地区新生儿杜氏肌营养不良症筛查

井淼; 王悦; 景晓莹; 毛新梅

doi:10.7499/j.issn.1008-8830.2309151

PDF(499 KB)

中国当代儿科杂志 ›› 2024, Vol. 26 ›› Issue (3) : 258-261. DOI: 10.7499/j.issn.1008-8830.2309151

论著·临床研究

宁夏地区新生儿杜氏肌营养不良症筛查

井淼, 王悦, 景晓莹, 毛新梅

作者信息 +

Screening for Duchenne muscular dystrophy in newborns in the Ningxia region

JING Miao, WANG Yue, JING Xiao-Ying, MAO Xin-Mei

Author information +

文章历史 +

摘要

目的初步评估宁夏地区男性新生儿人群中杜氏肌营养不良症（Duchenne muscular dystrophy, DMD）发病率，建立新生儿DMD筛查的临界值以区分新生儿正常人群和患病人群。方法采用免疫荧光分析法对10 000例男性新生儿足跟干血斑滤纸片中的肌酸激酶同工酶浓度进行检测，筛查出高于正常临界值的新生儿，召回进行血清肌酸激酶浓度测定，异常者通过基因检测以明确DMD诊断。结果共筛查10 000例男性新生儿，其中2例新生儿经基因检测确诊为DMD，初步估算宁夏地区男性新生儿DMD发病率为1/5 000；宁夏地区新生儿肌酸激酶同工酶浓度临界值为468.57 ng/mL。结论在宁夏地区进行新生儿DMD筛查是可行的，通过对DMD患儿的早期筛查、早期诊断和早期治疗，可以改善患儿生活质量，为家庭再生育赢得更短的决策时间。

Abstract

Objective To evaluate the incidence rate of Duchenne muscular dystrophy (DMD) in the male newborns in the Ningxia region and establish a critical threshold for screening DMD in newborns to distinguish between the normal population and affected individuals. Methods A total of 10 000 male newborns were screened using immunofluorescence analysis of creatine kinase isoenzyme concentrations in heel spot dried blood specimens. Newborns with the concentrations higher than the critical threshold were recalled for serum creatine kinase measurements. Genetic testing was performed to confirm diagnosis in cases showing abnormalities. Results Among the screened 10 000 male newborns, two were confirmed to have DMD through genetic testing, resulting in a preliminary estimated incidence rate of 1/5 000 for male newborns in the Ningxia region. The critical threshold for creatine kinase isoenzyme concentration in newborns in this region was determined to be 468.57 ng/mL. Conclusions Screening for DMD in newborns is feasible in the Ningxia region. Early screening, diagnosis, and treatment of DMD can improve the quality of life for affected individuals and help families make informed decisions regarding further pregnancies.

导出引用

井淼, 王悦, 景晓莹, 毛新梅. 宁夏地区新生儿杜氏肌营养不良症筛查[J]. 中国当代儿科杂志. 2024, 26(3): 258-261 https://doi.org/10.7499/j.issn.1008-8830.2309151

JING Miao, WANG Yue, JING Xiao-Ying, MAO Xin-Mei. Screening for Duchenne muscular dystrophy in newborns in the Ningxia region[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(3): 258-261 https://doi.org/10.7499/j.issn.1008-8830.2309151

参考文献

1 Duan D, Goemans N, Takeda S, et al. Duchenne muscular dystrophy[J]. Nat Rev Dis Primers, 2021, 7(1): 13. PMID: 33602943. PMCID: PMC10557455. DOI: 10.1038/s41572-021-00248-3.
2 Leiva-Cepas F, Monta?o Martínez A, López-López I. Update on Duchenne muscular dystrophy[J]. Semergen, 2021, 47(7): 472-481. PMID: 34417099. DOI: 10.1016/j.semerg.2021.06.008.
3 Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review[J]. Orphanet J Rare Dis, 2017, 12(1): 79. PMID: 28446219. PMCID: PMC5405509. DOI: 10.1186/s13023-017-0631-3.
4 Hammer S, Toussaint M, Volls?ter M, et al. Exercise training in Duchenne muscular dystrophy: a systematic review and meta-analysis[J]. J Rehabil Med, 2022, 54: jrm00250. PMID: 35642324. PMCID: PMC8862644. DOI: 10.2340/jrm.v53.985.
5 Matsuo M. Duchenne muscular dystrophy[J]. Southeast Asian J Trop Med Public Health, 1995, 26 Suppl 1: 166-171. PMID: 8629099.
6 Mao X, Li S, Ma Y, et al. Ethnic preference distribution of inborn errors of metabolism: a 4-year study in a multi-ethnic region of China[J]. Clin Chim Acta, 2020, 511: 160-166. PMID: 33058845. DOI: 10.1016/j.cca.2020.10.003.
7 Yang D, Su Z, Zhao M. Big data and reference intervals[J].Clin Chim Acta, 2022, 527: 23-32. PMID: 34999059. DOI: 10.1016/j.cca.2022.01.001.
8 Salari N, Fatahi B, Valipour E, et al. Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis[J]. J Orthop Surg Res, 2022, 17(1): 96. PMID: 35168641. PMCID: PMC8848641. DOI: 10.1186/s13018-022-02996-8.
9 McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study[J]. Lancet, 2018, 391(10119): 451-461. PMID: 29174484. DOI: 10.1016/S0140-6736(17)32160-8.
10 Pascual-Morena C, Cavero-Redondo I, Reina-Gutiérrez S, et al. Prevalence of neuropsychiatric disorders in Duchenne and Becker muscular dystrophies: a systematic review and meta-analysis[J]. Arch Phys Med Rehabil, 2022, 103(12): 2444-2453. PMID: 35839922. DOI: 10.1016/j.apmr.2022.05.015.
11 Katz SL, Mah JK, McMillan HJ, et al. Routine lung volume recruitment in boys with Duchenne muscular dystrophy: a randomised clinical trial[J]. Thorax, 2022, 77(8): 805-811. PMID: 35236763. PMCID: PMC9340020. DOI: 10.1136/thoraxjnl-2021-218196.
12 Crisafulli S, Sultana J, Fontana A, et al. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis[J]. Orphanet J Rare Dis, 2020, 15(1): 141. PMID: 32503598. PMCID: PMC7275323. DOI: 10.1186/s13023-020-01430-8.
13 Jia C, Zhao D, Li Y, et al. Newborn screening and genomic analysis of Duchenne muscular dystrophy in Henan, China[J]. Clin Chim Acta, 2023, 539: 90-96. PMID: 36516925. DOI: 10.1016/j.cca.2022.11.024.
14 Jia X, Jiang X, Huang Y. A pilot study of newborn screening for Duchenne muscular dystrophy in Guangzhou[J]. Heliyon, 2022, 8(10): e11071. PMID: 36281417. PMCID: PMC9587328. DOI: 10.1016/j.heliyon.2022.e11071.
15 Chien YH, Lee NC, Weng WC, et al. Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in Taiwan[J]. Neurol Sci, 2022, 43(7): 4563-4566. PMID: 35562557. PMCID: PMC9106269. DOI: 10.1007/s10072-022-06128-2.
16 Timonen A, Lloyd-Puryear M, Hougaard DM, et al. Duchenne muscular dystrophy newborn screening: evaluation of a new GSP? neonatal creatine kinase-MM kit in a US and Danish population[J]. Int J Neonatal Screen, 2019, 5(3): 27. PMID: 33072986. PMCID: PMC7510235. DOI: 10.3390/ijns5030027.
17 Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan[J]. Lancet Neurol, 2018, 17(5): 445-455. PMID: 29398641. PMCID: PMC5902408. DOI: 10.1016/S1474-4422(18)30026-7.
18 Passamano L, Taglia A, Palladino A, et al. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients[J]. Acta Myol, 2012, 31(2): 121-125. PMID: 23097603. PMCID: PMC3476854.
19 Miller AR, Condin CJ, McKellin WH, et al. Continuity of care for children with complex chronic health conditions: parents' perspectives[J]. BMC Health Serv Res, 2009, 9: 242. PMID: 20025770. PMCID: PMC2805629. DOI: 10.1186/1472-6963-9-242.
20 Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care[J]. Lancet Neurol, 2010, 9(2): 177-189. PMID: 19945914. DOI: 10.1016/S1474-4422(09)70272-8.
21 Chouteau WA, Burrows C, Wittekind SG, et al. Emergency planning as part of healthcare transition preparation for patients with Duchenne muscular dystrophy[J]. J Pediatr Nurs, 2021, 61: 298-304. PMID: 34450470. DOI: 10.1016/j.pedn.2021.08.003.